^
Association details:
| Biomarker: | ERCC2 positive + SYP negative + EGFR exon 21 mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
YO21 - A Rare Case of Pancreatic Metastasis from Primary Lung Adenocarcinoma. A Non Surgical Approach
Published date:
11/28/2022
Excerpt:
His histopathology was reviewed at the hospital and showed Adenocarcinoma Grade III, TTD-1 positive, Synaptophysin Negative….Histopathology showed Metastatic Adenocarcinoma from primary lesion with EGFR mutated at Exon 21 and ALK rearrangement not detected. Patient was offered palliative Radiation 20 Gray in 5 fraction for pain control to pancreatic mass and was offered Erlotinib 150mg once daily. There was significant response to treatment clinically and radiologically. Post 6 months there was no residual disease left.
